SciSparc Ltd. (NASDAQ:SPRC)
| Market Cap | 1.15M-94.8% |
| Revenue (ttm) | 679.00K-68.3% |
| Net Income | -8.22M-277.8% |
| EPS | -14.34-32.7% |
| Shares Out | 573.24K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,612,137 |
| Open | 4.20 |
| Previous Close | 3.63 |
| Day's Range | 1.63 - 5.33 |
| 52-Week Range | 1.63 - 40.41 |
| Beta | 2.55 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About SPRC
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SPRC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SPRC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SPRC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SPRC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SPRC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SPRC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SPRC
| ETF | Est. Holding Size |
|---|---|
| AVEMAvantis Emerging Markets Equity ETF | $1.52M |
| AVESAvantis Emerging Markets Value ETF | $214.74K |
| AVEEAvantis Emerging Markets Small Cap Equity ETF | $126.10K |
| AVXCAvantis Emerging Markets ex-China Equity ETF | $122.75K |
Estimated from each fund’s disclosed top holdings × AUM
SPRC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SPRC’s recent data — informational, not investment advice